Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib

Huang,Yuezhao; Wang,Kunyuan; Gu,Chengxin; Yu,Ganxiang; Zhao,Dan; Mai,Weijian; Zhong,Yun; Liu,Shiming; Nie,Yuqiang; Yang,Hui

doi:10.3892/or.2018.6552

Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib

Authors:
- Yuezhao Huang
- Kunyuan Wang
- Chengxin Gu
- Ganxiang Yu
- Dan Zhao
- Weijian Mai
- Yun Zhong
- Shiming Liu
- Yuqiang Nie
- Hui Yang
View Affiliations

Affiliations: Department of Gastroenterology, The Second Afﬁliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China, Department of Gastroenterology, The Second Afﬁliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China, Guangzhou Institute of Cardiovascular Disease, The Second Afﬁliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China, Guangzhou Institute of Cardiovascular Disease, The Second Afﬁliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China, Department of Gastroenterology, Guangzhou First People's Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
Published online on: July 10, 2018 https://doi.org/10.3892/or.2018.6552
Pages: 1525-1532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib resistance is one of the major factors affecting the prognosis of patients with hepatocellular carcinoma (HCC). Increasing evidence has indicated that certain traditional medicines can enhance the sensitivity of cancer cells to sorafenib. Berberine, an isoquinoline alkaloid, has been demonstrated to possess antitumor properties against various malignancies. However, the synergistic effect of the combination of berberine and sorafenib in HCC remains unknown. The aim of the present study was to determine the effects of berberine and sorafenib combination on the growth of liver cancer cells. Initially, it was observed that the combination of sorafenib and berberine exerted a synergistic inhibitory effect on the proliferation of SMMC‑7721 and HepG2 cells in a dose‑ and time‑dependent manner by an MTS assay. Edu staining and colony formation assays also revealed that the combination of 100 µM berberine and 4 µM sorafenib exhibited a significant anti‑proliferation effect on SMMC‑7721 and HepG2 cells. Furthermore, western blotting assay indicated that the expressions levels of cleaved poly(ADP‑ribose) polymerase and cleaved caspase‑3 increased, while those of the anti‑apoptotic protein B‑cell lymphoma 2 and vascular endothelial growth factor decreased. To the best of our knowledge, this is the first study to demonstrate that berberine sensitized liver cancer cells to sorafenib treatment. These results suggest that berberine combined with sorafenib is able to inhibit the proliferation of liver cancer cells and induce apoptosis, which provides evidence for further clinical investigation in HCC patients with sorafenib resistance.

View Figures

View References

1	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
2	Sia D, Villanueva A, Friedman SL and Llovet JM: Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 152:745–761. 2017. View Article : Google Scholar : PubMed/NCBI
3	Dutta R and Mahato RI: Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 173:106–117. 2017. View Article : Google Scholar : PubMed/NCBI
4	Keating GM: Sorafenib: A review in hepatocellular carcinoma. Target Oncol. 12:243–253. 2017. View Article : Google Scholar : PubMed/NCBI
5	Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH and Mohammed K: Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 67:422–435. 2017. View Article : Google Scholar
6	Adnane L, Trail PA, Taylor I and Wilhelm SM: Sorafenib (BAY 43–9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612. 2006. View Article : Google Scholar : PubMed/NCBI
7	Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, Hua SC, Yang M and Yuan Q: microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. Febs Lett. 585:1828–1834. 2011. View Article : Google Scholar : PubMed/NCBI
9	Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P, Caraglia M and Russo A: MicroRNA-125a-5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells. J Cell Physiol. 232:1907–1913. 2017. View Article : Google Scholar : PubMed/NCBI
10	Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
11	Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM and Jensen EH: Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery. 156:270–279. 2014. View Article : Google Scholar : PubMed/NCBI
12	Li S, Dai W, Mo W, Li J, Feng J, Wu L, Liu T, Yu Q, Xu S, Wang W, et al: By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. Int J Cancer. 141:2571–2584. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ayati SH, Fazeli B, Momtazi-Borojeni AA, Cicero A, Pirro M and Sahebkar A: Regulatory effects of berberine on microRNome in Cancer and other conditions. Crit Rev Oncol Hematol. 116:147–158. 2017. View Article : Google Scholar : PubMed/NCBI
14	Tillhon M, Guaman OL, Lombardi P and Scovassi AI: Berberine: New perspectives for old remedies. Biochem Pharmacol. 84:1260–1267. 2012. View Article : Google Scholar : PubMed/NCBI
15	Li-Weber M: Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 332:304–312. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tan W, Li Y, Chen M and Wang Y: Berberine hydrochloride: Anticancer activity and nanoparticulate delivery system. Int J Nanomedicine. 6:1773–1777. 2011. View Article : Google Scholar : PubMed/NCBI
17	Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian Y, Wu D, Zhao Y, Zhang Y, Chen X, et al: Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells. Oncogene. 36:6906–6918. 2017. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Yang S, Cai X, Dong J, Chen Z, Wang R, Zhang S, Cao H, Lu D, Jin T, et al: Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer. Oncotarget. 7:76076–76086. 2016.PubMed/NCBI
19	Li M, Zhang M, Zhang ZL, Liu N, Han XY, Liu QC, Deng WJ and Liao CX: Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB. Oncol Res. 25:233–239. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ayati SH, Fazeli B, Momtazi-Borojeni AA, Cicero A, Pirro M and Sahebkar A: Regulatory effects of berberine on microRNome in Cancer and other conditions. Crit Rev Oncol Hematol. 116:147–158. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y and Peng JY: Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine. Phytomedicine. 15:1062–1668. 2008. View Article : Google Scholar : PubMed/NCBI
22	Youn MJ, So HS, Cho HJ, Kim HJ, Kim Y, Lee JH, Sohn JS, Kim YK, Chung SY and Park R: Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull. 31:789–795. 2008. View Article : Google Scholar : PubMed/NCBI
23	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N and Kitai S: Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver Cancer. 4:263–273. 2015. View Article : Google Scholar : PubMed/NCBI
25	Blivet-Van EM, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O and Desbois-Mouthon C: Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol. 57:108–115. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhang Z, Zhou X, Shen H, Wang D and Wang Y: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study. BMC Med. 7:412009. View Article : Google Scholar : PubMed/NCBI
27	Yang X and Wu XZ: Main antitumor angiogenesis agents isolated from chinese herbal medicines. Mini Rev Med Chem. 15:1011–1023. 2015. View Article : Google Scholar : PubMed/NCBI
28	Lin M, Bi H, Yan Y, Huang W, Zhang G, Zhang G, Tang S, Liu Y, Zhang L, Ma J, et al: Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Oncotarget. 8:23436–23447. 2017.PubMed/NCBI
29	He QL, Minn I, Wang Q, Xu P, Head SA, Datan E, Yu B, Pomper MG and Liu JO: Targeted delivery and sustained antitumor activity of triptolide through glucose conjugation. Angew Chem Int Ed Engl. 55:12035–12039. 2016. View Article : Google Scholar : PubMed/NCBI
30	Sun Y, Xun K, Wang Y and Chen X: A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs. 20:757–769. 2009. View Article : Google Scholar : PubMed/NCBI
31	Su K, Hu P, Wang X, Kuang C, Xiang Q, Yang F, Xiang J, Zhu S, Wei L and Zhang J: Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer. Oncotarget. 7:45849–45862. 2016. View Article : Google Scholar : PubMed/NCBI
32	Chen Q, Qin R, Fang Y and Li H: Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell Physiol Biochem. 36:956–965. 2015. View Article : Google Scholar : PubMed/NCBI
33	Bao J, Huang B, Zou L, Chen S, Zhang C, Zhang Y, Chen M, Wan JB, Su H, Wang Y and He C: Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents. PLoS One. 10:e1392982015. View Article : Google Scholar
34	Hou D, Xu G, Zhang C, Li B, Qin J, Hao X, Liu Q, Zhang X, Liu J, Wei J, et al: Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis. 8:e30702017. View Article : Google Scholar : PubMed/NCBI
35	Das T, Sa G, Saha B and Das K: Multifocal signal modulation therapy of cancer: Ancient weapon targets. Mol Cell Biochem. 336:85–95. 2010. View Article : Google Scholar : PubMed/NCBI
36	Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L and Shen LM: Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation. Cancer Cell Int. 14:492014. View Article : Google Scholar : PubMed/NCBI
37	Fu L, Chen W, Guo W, Wang J, Tian Y, Shi D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and cytochrome-c/caspase signaling to suppress human cancer cell growth. PLoS One. 8:e692402013. View Article : Google Scholar : PubMed/NCBI
38	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
39	Wang H, Zhang C, Ning Z, Xu L, Zhu X and Meng Z: Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. Int J Oncol. 48:1229–12241. 2016. View Article : Google Scholar : PubMed/NCBI